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Dupilumab for hand eczema
To the Editor: Hand eczema is common, affecting about 10% of the general population over a 1-year period, with a poor long-term prognosis regardless of the etiology. 1 In severe cases it has a significant impact on quality of life, with major effects on social interactions, occupational success, and activities of daily living. 2 There are multiple etiologies and clinical patterns, but there is no consistent correlation between the etiology and the clinical pattern. Various classification schemes have existed over the years, but none has been generally accepted. In many patients it is not possible to identify the etiology, even after extensive investigation and long-term follow-up. Although many mild cases respond well to lifestyle changes, moisturizers, and intermittent topical steroids, there is no consistently effective topical or systemic therapy for severe disease.
The charts of all patients treated with dupilumab at a single center were reviewed to identify those with dermatitis involving primarily the hands. Three patients treated with dupilumab for severe, chronic, recalcitrant hand eczema were identified. Information on personal and family history of atopy, clinical aspects of the hand eczema, presence of dermatitis in other locations, history of response to prior therapies, and response to dupilumab treatment was collected. All 3 patients had substantial responses to dupilumab, ranging from 80% improvement to complete clearance.
Patient characteristics, efficacy of prior topical and systemic steroids, and response to dupilumab are presented in Table I . All patients were treated with the standard US Food and Drug Administratione approved dosing of 600 mg subcutaneously on day 1 followed by 300 mg subcutaneously every 14 days. It should be noted that before dupilumab therapy, all 3 patients underwent comprehensive patch testing and no relevant allergens were detected.
Dupilumab is the first US Food and Drug Administrationeapproved therapy for moderate-tosevere atopic dermatitis. Its efficacy, both as monotherapy and in conjunction with corticosteroids, has been demonstrated in multiple double-blind, randomized, clinical trials. 3 In all the reported trials inclusion criteria indicated that atopic dermatitis must affect greater than 10% of the body surface area. 3 Because the palm including the fingers comprises 1% of the body surface area, the studies specifically excluded patients with atopic dermatitis limited to the hands. Although the reported patients do not fit the stereotypic pattern of extrinsic atopic dermatitis characterized by a combination of typical cutaneous features, childhood onset, and mucosal allergies (rhinitis or asthma), they do fit the well-described intrinsic atopic dermatitis phenotype characterized by typical skin lesions, adult onset, and lack of mucosal allergies. 4 In addition, they meet the Hanifin and Rajka criteria for diagnosis of atopic dermatitis. 5 On the basis of searches of PubMed, Embase, and the Cochrane Library for all articles with the term dupilumab anywhere in the title or abstract, this is the first report of dupilumab therapy for patients with dermatitis limited primarily to the palms. The positive results in these 3 patients suggest that dupilumab can be considered as a therapeutic option in patients with palmar hand eczema who meet the diagnostic criteria for atopic dermatitis. Reprints not available from the author. There are few longitudinal studies examining the need for rescreening in this patient population. We sought to determine the TB conversion rate in patients undergoing anti-TNF treatment in Iowa, an 
